Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
A Phase 2b randomized clinical trial published in JAMA Psychiatry found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive...
A Phase 2b randomized clinical trial published in JAMA Psychiatry found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive...
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD).
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD).
Perinatal depression symptoms improved significantly during pregnancy and early postpartum regardless of enhanced prenatal care format, according to recent study findings.
Perinatal depression symptoms improved significantly during pregnancy and early postpartum regardless of enhanced prenatal care format, according to recent study findings.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
